These Analysts Increase Their Forecasts On Praxis Precision Medicines After Q2 Results
These Analysts Increase Their Forecasts On Praxis Precision Medicines After Q2 Results
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) reported a loss for the second quarter on Tuesday.
Praxis Precision Medicines, Inc. (纳斯达克:PRAX)周二公布了第二季度的亏损。
The company posted a quarterly loss of $1.74 per share which beat the analyst consensus estimate for a loss of $2.31 per share. The company reported quarterly sales of $357.000 thousand which missed the analyst consensus estimate of $870.000 thousand.
公司每股公布了1.74美元的季度亏损，超过了分析师预期的每股2.31美元的亏损。公司公布了357000美元的季度销售额，低于分析师预期的870000美元。
"In the second quarter we continued to advance our entire portfolio, and we are poised to soon have up to four programs in registrational stage. The Essential3 program continues to progress well, with a pre-planned interim analysis of Study 1 to be conducted later this year. We remain on track for a successful topline readout enabling an NDA filing in 2025," said Marcio Souza, president and chief executive officer of Praxis. "We look forward to sharing topline results of the EMBOLD study for relutrigine, formerly known as PRAX-562, in SCN2A and 8A patients later this quarter and believe these indications could be the tip of the iceberg for future application of PRAX-562 in other DEEs."
Praxis的总裁兼首席执行官Marcio Souza说:"在第二季度，我们继续推进整个产品组合，很快将会有多达四个申请登记阶段的项目。Essential3项目仍然顺利，预计今年晚些时候将进行预先计划的研究1中期分析。我们仍然按计划进行，以使顶线数据后在2025年提交新药申请(NDA)", "我们期待在这个季度后期分享relutrigine(以前称为PRAX-562)在SCN2A和8A患者中EMBOLD研究的顶线结果，并认为这些指标可能只是PRAX-562在其他DEE应用的冰山一角。
PRAX shares fell 1.7% to trade at $51.33 on Wednesday.
周三，PRAX股票下跌1.7%，报51.33美元。
These analysts made changes to their price targets on PRAX following earnings announcement.
这些分析师在收益公告后对PRAX的价格目标进行了调整。
- Wedbush analyst Laura Chico maintained Praxis Precision Medicine with a Neutral rating and raised the price target from $40 to $48.
- Guggenheim analyst Yatin Suneja maintained the stock with a Buy rating, while increasing the price target from $155 to $170.
- Oppenheimer analyst Francois Brisebois reiterated Praxis Precision Medicine with an Outperform rating and maintained a price target of $134.
- Needham analyst Ami Fadia reiterated the stock with a Buy and maintained a price target of $145.
- Wedbush分析师Laura Chico保持Praxis Precision Medicine的中立评级，并将价格目标从40美元升至48美元。
- Guggenheim分析师Yatin Suneja保持买入评级，将价格目标从155美元升至170美元。
- Oppenheimer分析师Francois Brisebois重申Praxis Precision Medicine的跑赢大盘评级，并维持134美元的价格目标。
- Needham分析师Ami Fadia重申买入评级，并维持145美元的价格目标。
Read More:
更多阅读：
- Wall Street's Most Accurate Analysts Weigh In On 3 Tech Stocks With Over 3% Dividend Yields
- 华尔街最准确的分析师们对3只科技股的股息收益率超过3％进行了权衡
Considering buying PRAX stock? Here's what analysts think:
考虑购买PRAX股票？以下是分析师的看法：
